Brokerages Set TScan Therapeutics, Inc. (NASDAQ:TCRX) PT at $6.00

TScan Therapeutics, Inc. (NASDAQ:TCRX) has received an average rating of “Hold” from the six ratings firms that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and three have issued a buy recommendation on the company. The average 1 year price target among brokers that have covered the stock in the last year is $6.00.

A number of equities research analysts have recently issued reports on TCRX shares. Wedbush increased their price target on shares of TScan Therapeutics from $4.00 to $5.00 and gave the stock an “outperform” rating in a report on Thursday, March 5th. Wall Street Zen downgraded shares of TScan Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, May 9th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of TScan Therapeutics in a research note on Tuesday, April 21st.

TScan Therapeutics Trading Down 3.7%

Shares of TScan Therapeutics stock opened at $0.98 on Friday. TScan Therapeutics has a 12-month low of $0.88 and a 12-month high of $2.57. The company has a market cap of $64.17 million, a price-to-earnings ratio of -1.02 and a beta of 1.03. The company has a current ratio of 6.65, a quick ratio of 6.65 and a debt-to-equity ratio of 0.34. The company’s 50-day moving average price is $1.10 and its 200-day moving average price is $1.07.

TScan Therapeutics (NASDAQ:TCRX) last announced its quarterly earnings results on Wednesday, May 6th. The company reported ($0.22) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.22). TScan Therapeutics had a negative net margin of 1,360.61% and a negative return on equity of 91.94%. The firm had revenue of $0.98 million for the quarter, compared to the consensus estimate of $2.50 million. On average, equities analysts expect that TScan Therapeutics will post -1.11 earnings per share for the current fiscal year.

Institutional Investors Weigh In On TScan Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Virtu Financial LLC raised its stake in TScan Therapeutics by 431.1% in the third quarter. Virtu Financial LLC now owns 60,480 shares of the company’s stock valued at $110,000 after purchasing an additional 49,092 shares in the last quarter. Qube Research & Technologies Ltd purchased a new stake in TScan Therapeutics in the second quarter valued at approximately $99,000. Voleon Capital Management LP purchased a new stake in TScan Therapeutics in the third quarter valued at approximately $87,000. Marshall Wace LLP purchased a new stake in TScan Therapeutics in the second quarter valued at approximately $78,000. Finally, Boothbay Fund Management LLC raised its stake in TScan Therapeutics by 50.0% in the second quarter. Boothbay Fund Management LLC now owns 24,363 shares of the company’s stock valued at $35,000 after purchasing an additional 8,121 shares in the last quarter. 82.83% of the stock is owned by hedge funds and other institutional investors.

TScan Therapeutics Company Profile

TScan Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of T-cell receptor (TCR) therapies for the treatment of cancer. Leveraging its proprietary T-Scan platform, the company seeks to identify high-affinity TCRs that recognize intracellular tumor antigens presented on the surface of cancer cells. TScan’s approach aims to broaden the reach of immunotherapy beyond current targets by unlocking a wider array of cancer-associated proteins.

The company’s pipeline includes multiple preclinical and early-stage clinical programs in both hematologic malignancies and solid tumors.